Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?

被引：2
作者：
Assi, Tarek [1 ]
Mir, Olivier [2 ]
机构：
[1] Gustave Roussy, Dept Canc Med, Villejuif, France
[2] Gustave Roussy, Dept Ambulatory Canc Care, Villejuif, France
来源：
IMMUNOTHERAPY | 2022年 / 14卷 / 05期
关键词：
checkpoint inhibitors; hyperprogression; immunotherapy; leiomyosarcoma; sarcoma; soft tissue; SOFT-TISSUE SARCOMA; OPEN-LABEL; PEMBROLIZUMAB; MULTICENTER; DOXORUBICIN; NIVOLUMAB; RESISTANCE; IPILIMUMAB; CANCER; PTEN;
D O I：
10.2217/imt-2021-0297
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：271 / 274
页数：4
相关论文
共 34 条
  • [1] Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
    Adashek, Jacob J.
    Subbiah, Ishwaria M.
    Matos, Ignacio
    Garralda, Elena
    Menta, Arjun K.
    Ganeshan, Dhakshina Moorthy
    Subbiah, Vivek
    [J]. TRENDS IN CANCER, 2020, 6 (03): : 181 - 191
  • [2] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka
    George, Saby
    Olencki, Thomas E.
    Tarazi, Jamal C.
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2018, 19 (03) : 405 - 415
  • [3] Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
    Beck, A. H.
    Lee, C-H
    Witten, D. M.
    Gleason, B. C.
    Edris, B.
    Espinosa, I.
    Zhu, S.
    Li, R.
    Montgomery, K. D.
    Marinelli, R. J.
    Tibshirani, R.
    Hastie, T.
    Jablons, D. M.
    Rubin, B. P.
    Fletcher, C. D.
    West, R. B.
    van de Rijn, M.
    [J]. ONCOGENE, 2010, 29 (06) : 845 - 854
  • [4] Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
    Ben-Ami, Eytan
    Barysauskas, Constance M.
    Solomon, Sarah
    Tahlil, Kadija
    Malley, Rita
    Hohos, Melissa
    Polson, Kathleen
    Loucks, Margaret
    Severgnini, Mariano
    Patel, Tara
    Cunningham, Amy
    Rodig, Scott J.
    Hodi, F. Stephen
    Morgan, Jeffrey A.
    Merriam, Priscilla
    Wagner, Andrew J.
    Shapiro, Geoffrey I.
    George, Suzanne
    [J]. CANCER, 2017, 123 (17) : 3285 - 3290
  • [5] Immunotherapy for sarcomas: new frontiers and unveiled opportunities
    Birdi, Harsimrat Kaur
    Jirovec, Anna
    Cortes-Kaplan, Serena
    Werier, Joel
    Nessim, Carolyn
    Diallo, Jean-Simon
    Ardolino, Michele
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [7] Hyperprogressive disease: recognizing a novel pattern to improve patient management
    Champiat, Stephane
    Ferrara, Roberto
    Massard, Christophe
    Besse, Benjamin
    Marabelle, Aurelien
    Soria, Jean-Charles
    Ferte, Charles
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) : 748 - 762
  • [8] Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    D'Ambrosio, Lorenzo
    Touati, Nathan
    Blay, Jean-Yves
    Grignani, Giovanni
    Flippot, Ronan
    Czarnecka, Anna M.
    Piperno-Neumann, Sophie
    Martin-Broto, Javier
    Sanfilippo, Roberta
    Katz, Daniela
    Duffaud, Florence
    Vincenzi, Bruno
    Stark, Daniel P.
    Mazzeo, Filomena
    Tuchscherer, Armin
    Chevreau, Christine
    Sherriff, Jenny
    Estival, Anna
    Litiere, Saskia
    Sents, Ward
    Ray-Coquard, Isabelle
    Tolomeo, Francesco
    Le Cesne, Axel
    Rutkowski, Piotr
    Stacchiotti, Silvia
    Kasper, Bernd
    Gelderblom, Hans
    Gronchi, Alessandro
    [J]. CANCER, 2020, 126 (11) : 2637 - 2647
  • [9] Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
    D'Angelo, Sandra P.
    Mahoney, Michelle R.
    Van Tine, Brian A.
    Atkins, James
    Milhem, Mohammed M.
    Jahagirdar, Balkrishna N.
    Antonescu, Cristina R.
    Horvath, Elise
    Tap, William D.
    Schwartz, Gary K.
    Streicher, Howard
    [J]. LANCET ONCOLOGY, 2018, 19 (03) : 416 - 426
  • [10] Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
    De Wispelaere, Wout
    Annibali, Daniela
    Tuyaerts, Sandra
    Lambrechts, Diether
    Amant, Frederic
    [J]. CANCERS, 2021, 13 (09)
1234